| Chronic rhinosinusitis with multiple nasal polyps
Dupixent vs Tezspire
Side-by-side clinical, coverage, and cost comparison for chronic rhinosinusitis with multiple nasal polyps.Deep comparison between: Dupixent vs Tezspire with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTezspire has a higher rate of injection site reactions vs Dupixent based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tezspire but not Dupixent, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Dupixent
Tezspire
At A Glance
SC injection
Every 2 weeks
IL-4Ra antagonist
SC injection
Every 4 weeks
TSLP blocker
Indications
- Dermatitis, Atopic
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- Eosinophilic esophagitis
- Prurigo nodularis
- Chronic Obstructive Airway Disease
- Chronic Spontaneous Urticaria
- Bullous pemphigoid
- Allergic Fungal Rhinosinusitis
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
Dosing
Dermatitis, Atopic Adults: 600 mg initial dose, then 300 mg SC Q2W; pediatric patients 6 months to 5 years: weight-based Q4W without loading dose; pediatric patients >=6 years: weight-based loading dose then Q2W or Q4W.
Asthma Adults and pediatric >=12 years: 400 mg or 600 mg loading dose, then 200 mg or 300 mg SC Q2W; pediatric 6-11 years: weight-based Q2W or Q4W without loading dose.
Chronic rhinosinusitis with multiple nasal polyps 300 mg SC Q2W for adults and pediatric patients >=12 years.
Eosinophilic esophagitis SC weight-based dosing for patients >=1 year weighing >=15 kg: 200 mg Q2W (15 to <30 kg), 300 mg Q2W (30 to <40 kg), or 300 mg weekly (>=40 kg).
Prurigo nodularis Adults: 600 mg initial dose, then 300 mg SC Q2W.
Chronic Obstructive Airway Disease Adults: 300 mg SC Q2W.
Chronic Spontaneous Urticaria Adults: 600 mg initial dose, then 300 mg SC Q2W; pediatric 12-17 years: weight-based 400 mg or 600 mg loading, then 200 mg or 300 mg Q2W.
Bullous pemphigoid Adults: 600 mg initial dose, then 300 mg SC Q2W in combination with a tapering course of oral corticosteroids.
Allergic Fungal Rhinosinusitis Adults: 300 mg SC Q2W; pediatric 6-17 years: weight-based Q2W or Q4W (15 to <30 kg: 300 mg Q4W; 30 to <60 kg: 200 mg Q2W; >=60 kg: 300 mg Q2W).
Asthma, Chronic rhinosinusitis with multiple nasal polyps 210 mg administered subcutaneously once every 4 weeks.
Contraindications
- Known hypersensitivity to dupilumab or any excipients of DUPIXENT
- Known hypersensitivity to tezepelumab-ekko or any of its excipients
Adverse Reactions
Most common (>=1%) Injection site reactions, conjunctivitis, oral herpes, blepharitis, keratitis, eye pruritus, other herpes simplex virus infection, dry eye
Serious Hypersensitivity reactions, conjunctivitis and keratitis, psoriasis, arthralgia and psoriatic arthritis, parasitic (helminth) infections
Postmarketing Angioedema, psoriatic arthritis, facial skin reactions (erythema, rash, scaling, edema, papules, pruritus, burning, pain), new-onset psoriasis, vasculitis
Most common (>=3%) Nasopharyngitis, upper respiratory tract infection, pharyngitis, arthralgia, back pain, epistaxis, influenza, injection site reaction
Serious Serious cardiac adverse events (incidence rate 1.08 per 100 patient-years in TEZSPIRE vs 0.21 in placebo in long-term extension trial)
Postmarketing Anaphylaxis
Pharmacology
Dupilumab is a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 signaling by binding to the IL-4Ra subunit shared by the IL-4 and IL-13 receptor complexes, blocking cytokine-induced inflammatory responses including release of proinflammatory cytokines, chemokines, nitric oxide, and IgE.
TSLP blocker; tezepelumab-ekko is a human monoclonal antibody (IgG2lambda) that binds human thymic stromal lymphopoietin (TSLP) and blocks its interaction with the heterodimeric TSLP receptor, thereby reducing inflammatory biomarkers including blood eosinophils, IgE, FeNO, IL-5, and IL-13.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Dupixent
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (2/12)
Tezspire
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Dupixent
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (6/8)
Tezspire
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Dupixent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Tezspire
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell Foundation: Asthma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DupixentView full Dupixent profile
TezspireView full Tezspire profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.